| 000 | 01199 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250514022240.0 | ||
| 264 | 0 | _c20020221 | |
| 008 | 200202s 0 0 eng d | ||
| 022 | _a0077-8923 | ||
| 024 | 7 |
_a10.1111/j.1749-6632.2001.tb04039.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKomm, B S | |
| 245 | 0 | 0 |
_aDeveloping a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. _h[electronic resource] |
| 260 |
_bAnnals of the New York Academy of Sciences _cDec 2001 |
||
| 300 |
_a317-26 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aClinical Trials as Topic _xstandards |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aDrug Evaluation _xstandards |
| 650 | 0 | 4 |
_aEstrogens _xchemistry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndoles _xpharmacology |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 |
_aSelective Estrogen Receptor Modulators _xpharmacology |
| 700 | 1 | _aLyttle, C R | |
| 773 | 0 |
_tAnnals of the New York Academy of Sciences _gvol. 949 _gp. 317-26 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1749-6632.2001.tb04039.x _zAvailable from publisher's website |
| 999 |
_c11706482 _d11706482 |
||